Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | CTPS1 | P17812 | 7/20 | 0.43 |
| ▸ | CTPS2 | Q9NRF8 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21044009 | 0.89 | CTPS1 (0.44) | KMT2AMEN1CTPS1CTPS2POLB | |
| SCHEMBL21044568 | 0.86 | KDM1A (0.47) | KMT2AMEN1KDM1ACTPS1CTPS2 | |
| SCHEMBL22869127 | 0.85 | KMT2A (0.43) | KMT2AMEN1CTPS1CTPS2POLB | |
| SCHEMBL22869126 | 0.83 | CTPS1 (0.44) | KMT2AMEN1CTPS1CTPS2POLB | |
| SCHEMBL21044168 | 0.82 | CTPS1 (0.43) | KMT2AMEN1CTPS1CTPS2POLB | |
| SCHEMBL21044015 | 0.80 | CTPS1 (0.58) | KMT2AMEN1CTPS1CTPS2ATAD2 | |
| SCHEMBL21044395 | 0.79 | CTPS1 (0.39) | KMT2AMEN1CTPS1CTPS2POLB | |
| SCHEMBL22869171 | 0.79 | KMT2A (0.41) | KMT2AMEN1CTPS1CTPS2POLB | |
| SCHEMBL21044083 | 0.79 | CTPS1 (0.39) | KMT2AMEN1CTPS1CTPS2POLB | |
| SCHEMBL21076799 | 0.75 | CTPS1 (0.46) | KMT2AMEN1CTPS1CTPS2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | KMT2A 4442/4885MEN1 4301/4885KDM1A 4398/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | KMT2A 4127/4885MEN1 192/4885KDM1A 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.